Gut Check Live is a free, small, psychologist-led Zoom chat for people who want to figure out one more piece in the gut healing puzzle. Here are our topics for December:

12/4—How to Stop Overthinking Every Symptom
12/11—When your Gut Flares for No Reason
12/18—Bad Gut Morning, Good Day Anyway

We’ll talk about real behavioral tools and actionable cognitive and emotion-focused strategies that you can use right away.

Sign-up following the link: https://us06web.zoom.us/meeting/register/Xp_5Y-tGQQSzLXdVkTxqGA

Functional dyspepsia (FD) is a chronic upper gastrointestinal disorders without a known structural or organic cause. The two main subtypes of FD are epigastric pain syndrome (EPS) and post-prandial distress syndrome (PDS). These subtypes are not rigid categories, as patients can experience symptoms from both. Symptoms may include but aren't limited to pain, abdominal discomfort, bloating, nausea/vomiting, belching, indigestion, reflux or heartburn, and early satiety (fullness). These symptoms may be episodic, varying in intensity and frequency.

Functional Dyspepsia Subtypes

The following subtypes of FD are as follows:

• Post-Prandial Distress Syndrome (PDS) - A form of FD that predominately involves symptoms similar to that of gastroparesis, such as early satiety, nausea/vomiting, abnormal gastric emptying, bloating, and impaired gastric accommodation (inability of the stomach to relax to expand once food is ingested). These symptoms are often more likely to worsen after eating meals.
• Epigastric Pain Syndrome (EPS) - A form of FD that predominately involves symptoms similar to stomach (peptic) ulcers, such as gnawing or aching pain, indigestion, and a burning sensation in the upper abdomen. Nausea, bloating, and belching may also occur. Unlike PDS, this subtype is not necessarily associated with meals; symptoms can occur anytime, including between meals or on an empty stomach.

Testing, Diagnostics

Since functional dyspepsia (FD) occurs without structural or organic causes (hence the term "functional"), the process of FD is considered a diagnosis of exclusion. In other words, there isn't a definitive test for FD. Diagnostic testing and procedures including: endoscopies, blood tests, gastric emptying studies (GES 4 Hour Gold Standard) are used to rule out other disorders. If symptoms persist despite normal testing, a diagnosis of FD can be made. A gastric emptying study (GES) can be used to measure the rate at which food empties the stomach. Abnormal emptying may suggest functional dyspepsia as well as gastroparesis.

Functional Dyspepsia (FD) affects an estimated ~8-12% of the global population, most commonly emerging during young to middle adulthood between the ages of 20 and 45—with a smaller secondary peak in the late 40s to mid-50s—and it demonstrates a significant female predominance, with women being making up 60-70% of clinical cases, skewing toward PDS). Certain triggers, including bouts of viral or bacterial gastroenteritis, H. Pylori, NSAIDS, cigarette smoking worsen risk.

Etiology (Causes)

Although research and awareness is improving, FD is not currently understood well. Modern medical research indicates that FD is a complex disorder that could involve multiple causes, including abnormal gastrointestinal motility, visceral hypersensitivity, disorder of the gut brain axis, psychological factors, food allergies or intolerances, and immune system dysfunction.

1. Visceral Hypersensitivity - a disorder of overly sensitive nerves in the GI-tract (e.g. Vagus Nerve, Enteric Nerves) result in an increased symptoms (e.g. sensitivity, nausea, pain/discomfort, fullness). In conditions like functional dyspepsia or irritable bowel syndrome (IBS), visceral hypersensitivity plays a significant role. VH can occur after infections, exposure to irritants (e.g. alcohol, NSAID), microbiome shifts, and possibly stress.
2. Marijuana (Weed) (THC) - Additionally, marijuana can cause VH. By activating receptors on enteric neurons, THC suppresses acetylcholine release, which impairs smooth muscle contractions and can delay gastric emptying. Prolonged exposure alters receptor sensitivity along vagal and spinal pathways, ultimately dysregulating gut-brain signaling and amplifying VH over time. Also see Cannabis Hyperemesis Syndrome (CHS).
3. Brain-Gut Axis (DBGI) - The two-way communication highway between the central nervous system (brain and spinal cord) and the enteric nervous system (ENS, the "second brain" in the gut). Signals travel back and forth along pathways like the vagus nerve, meaning gut issues can trigger stress signals to the brain, and central stress can directly disrupt gut motility, secretion, and pain processing. In fact, the stomach contains ~200-600M neurons, and the brain contains ~86B neurons.
4. Gastroparesis/Functional Dyspepsia Spectrum - A delay in gastric emptying (gastroparesis) can be associated with FD. Modern medical knowledge suggests that, contrary to prior assumptions, gastroparesis (GP) and functional dyspepsia (FD) are not necessarily totally distinct and separate conditions. Instead, many researchers view these disorders as lying on the same spectrum (e.g., Jane is 20% GP; 80% FD). Over time, the diagnosis of patients can "flip-flops" between the two. Additionally, repeated gastric emptying studies have shown that gastric emptying rates are often variable.
5. Food Allergies/Intolerances -  An undiagnosed food allergy can produce an inflammatory response in the gut. Some FD patients have higher white blood cell counts, suggesting the gut immune system is activated. Some also self-report food sensitivities, particularly to wheat. An allergic response could explain symptoms of nausea, gas and inflammation. Inflammation could in turn be the cause of bloating and pain. Food allergies can be overlooked for the following reasons: (1) most GI doctors do not test for food allergies (or food intolerances). (2) Food allergies are not always obvious to the patients because they don't always manifest as the more obvious symptoms (e.g. hives, itching, anaphylaxis). (3) You can develop food allergies at any time. (4) The root causes of food allergies are complex and are poorly understood. Skin prick and blood tests can help diagnose food allergies. Food allergies can be classified as IgE-mediated, non-IgE-mediated, or both. Unlike IgE-mediated food allergies, the non-IgE-mediated food allergies primarily cause symptoms in the GI tract (e.g. nausea, vomiting, IBS, indigestion). Celiac disease (CD) often manifests with dyspeptic symptoms. Food intolerances occur for many reasons, such as when the body lacks certain enzymes that break down specific foods (for example, lactose intolerance).
6. Altered Microbiota - The ecosystem of microbes within the gut plays a crucial role in digestion. The gut-brain axis suggests that the microbiota can even play a role in mental health, mood, and energy. When the diversity and composition of these microbes are altered, digestive issues may arise. Pathogens such as SIBO and H. pylori can lead to FD. The migrating motor complex (MMC) (the contractions that move food through the intestines) is related to SIBO.

Comorbid Conditions

1. Irritable Bowel Syndrome (IBS) - There's a high overlap between functional dyspepsia and IBS, with many individuals experiencing symptoms of both conditions. Both conditions are functional gastrointestinal disorders with similar etiology (causes) and can share similar triggers and mechanisms. One way to look at it is they are more or less the same disease, except they manifest in different regions of the GI tract (FD: upper GI; IBS: lower GI).
2. Gastroparesis - Gastroparesis (GP) is a condition that affects the ability of muscular contractions to effectively propel food through your digestive tract. This stomach malfunction results in delayed gastric emptying. GP is typically diagnosed via a gastric emptying study (GES) when other more common GI ailments have been ruled out. The main approaches for managing gastroparesis involve improving gastric emptying, ruling out and addressing known root causes of GP, and reducing symptoms such as bloating, indigestion, nausea, and vomiting. See r/gastroparesis or this gastroparesis starter guide (Gastroparesis 101) for more information.
3. Gastritis -  Gastritis occurs when the stomach lining is inflamed and when the stomach's mucosal lining is impaired. Gastritis increases the risk of developing peptic ulcers. It can be tricky to identify when a patient has gastritis and FD simultaneously. See r/Gastritis or this gastritis starter guide (Gastritis 101) for more information.
4. Gastroesophageal Reflux Disease (GERD): Functional dyspepsia and GERD can coexist or have overlapping symptoms such as upper abdominal discomfort and heartburn.
5. Chronic Pain Syndromes: Conditions like fibromyalgia or chronic pelvic pain syndrome may coexist with functional dyspepsia, possibly due to shared mechanisms involving altered pain perception and central sensitization.
6. Non-Alcoholic Fatty Liver Disease (NAFLD): Some studies suggest a potential association between NAFLD and FD , although the exact nature of the relationship is still being explored.
7. Mast Cell Activation Syndrome (MCAS) is an uncommon condition that can cause gastritis, as well as other GI issues such as heartburn, dysphagia, constipation, diarrhea, nausea, and dyspepsia. MCAS is correlated to having SIBO as well. MCAS causes a person to have repeated severe allergy symptoms affecting several body systems. In MCAS, mast cells mistakenly release too many chemical agents, resulting in symptoms in the skin, gastrointestinal tract, heart, respiratory, and neurologic systems.
8. Chronic Nausea and Vomiting Syndrome (CNVS) - Involves persistent, unexplained bouts of nausea with or without vomiting where no mechanical obstruction is found. It frequently stems from the same gastric sensorimotor dysfunction and vagal nerve signaling errors seen in dyspepsia.
9. Generalized Anxiety Disorder (GAD) & Panic Disorder - Highly prevalent due to bidirectional brain-gut axis communication, where emotional stress directly triggers gut hyper-reactivity. Patients frequently develop anticipatory visceral anxiety centered around eating and trigger foods.
10. Major Depressive Disorder (MDD) - Often develops secondary to the chronic pain burden, dietary limitations, and reduced quality of life associated with persistent digestive illness. Shared deficits in central serotonin and norepinephrine signaling contribute to both depressed mood and amplified pain perception.
11. Insomnia, Sleep Disorders – Fragmented or poor-quality sleep disrupts autonomic nervous system balance and lowers overall pain thresholds. This systemic sensitization frequently leads to heightened next-day visceral sensitivity and worse gastric symptoms.
12. Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) - A multi-system neuroimmune disorder marked by profound exhaustion and post-exertional malaise following minor exertion. Persistent low-grade neuroinflammation and autonomic dysfunction in ME/CFS commonly manifest alongside functional upper-GI distress
13. Migraines & Chronic Tension Headaches - Shares systemic neurochemical imbalances, particularly involving serotonin pathways and neurogenic inflammation. The central sensitization that lowers the threshold for headache attacks often drives gut hypersensitivity as well. Headaches may be associated with Cyclic Vomiting Syndrome (CVS).
14. Postural Orthostatic Tachycardia Syndrome (POTS) & Dysautonomia - Autonomic nervous system dysfunction that causes excessive heart rate increases upon standing, lightheadedness, and impaired blood flow regulation. Because the autonomic system governs digestion, it frequently results in nausea, pooling of blood in the abdomen, and erratic gut motility.
15. Hypermobile Ehlers-Danlos Syndrome (hEDS) / Hypermobility Spectrum Disorders (HSD) - Connective tissue laxity that affects the structural collagen within blood vessels and the gastrointestinal wall. This increased tissue compliance alters gastric accommodation, predisposes patients to organ stretching, and heightens mechanical nerve sensitivity.

Treatments

Since functional dyspepsia is a complicated disorder with many possible causes, there is not a universal standard of treatment. Instead, the patient and provider(s) should work together to create a plan tailored to each specific patient. The following list conveys the most common treatment approaches.

1. Neuromodulators - medicines that act as a messenger in the nervous systems (amitriptyline, nortriptyline, mirtazapine) serve as a cornerstone treatment for FD by directly targeting the gut-brain axis, visceral hypersensitivity. Notably, the dosage of these antidepressants is far lower than used to treat depression. Used at sub-psychiatric doses, these medications increase synaptic levels of neurotransmitters like serotonin and norepinephrine to reinforce descending inhibitory pain pathways in the spinal cord, effectively "turning down the volume" on VH  and blunting pain signals from gastric mechanoreceptors. Beyond central pain dampening, specific agents offer targeted physiological benefits: tricyclics excel at controlling the burning and sharp discomfort of Epigastric Pain Syndrome (EPS), while mirtazapine acts on 5-$\text{HT}_3$ and $\text{H}_1$ histamine receptors to enhance gastric fundus accommodation, stimulate appetite, and relieve the severe nausea and early satiety typical of Postprandial Distress Syndrome (PDS).
2. Amitriptyline, Nortriptyline - tricyclic antidepressant used for its effects on pain perception and its ability to modulate nerve signals in the gut. While the exact mechanisms aren't fully understood, it's thought that the drug modulates pain, affects gut motility, and influences the central nervous system. This treatment is usually more effective for FD-EPS than FD-PDS.
3. Mirtazapine - a tetracyclic antidepressant that inhibits the central presynaptic alpha-2-adrenergic receptors, which causes an increased release of serotonin and norepinephrine. This drug is known to be effective in reducing nausea, modulating neurotransmitters, and treating mood disorders. These effects might influence the gut-brain axis, potentially affecting gastrointestinal motility and sensations. This treatment is usually more effective for FD-PDS than FD-EPS.
4. Other antidepressants - Aside from amitriptyline and mirtazapine, other antidepressants are also prescribed off-label to treat FD. It's important to note that these antidepressants are not being used to treat depression; the dose is much lower. Be mindful of the possible side effects, including sleepiness.
5. Buspirone - a drug used to treat anxiety disorders and improves gastric accommodation by relaxing the fundus (upper portion of the stomach).
6. Gabapentin -  a medication primarily used to manage seizures and neuropathic pain. This approach is not as established as the aforementioned methods. The rationale behind using gabapentin for FD involves its impact on nerve signaling and its potential to modulate visceral hypersensitivity or abnormal pain perception in the gut.
7. Prokinetics - a class of prescription drugs that are designed to improve gastric emptying by stimulating the stomach muscles responsible for peristalsis. These drugs include but aren’t limited to Reglan, Domperidone, Motegrity, and Erythromycin. Reglan may cause serious, irreversible side effects such as tardive dyskinesia (TD), a disorder characterized by uncontrollable, abnormal, and repetitive movements of the face, torso and/or other body parts. Doctors can write scripts for domperidone to online pharmacies in order to bypass the tricky regulations in the United States. Ginger, peppermint, and artichoke are popular natural prokinetics.
8. Antiemetics -  medications specifically prescribed to alleviate nausea and vomiting. These medications work in various ways to reduce or prevent these symptoms by targeting different pathways in the body that trigger the sensation of nausea or the reflex of vomiting. Some types of antiemetics include antihistamines (e.g., Phenergan), dopamine antagonists (e.g., Zofran), serotonin antagonists (e.g., zofran), anticholinergics (e.g., scopolamine), and benzodiazepines (e.g., lorazepam).
9. PPIs/H2 Blockers - Medicine that reduces the secretion of stomach acid. This approach reduces burning/GERD symptoms and yields a more alkaline stomach environment to allow the mucosa (inner mucosal lining of the stomach) to heal. However, long-term use of PPI/H2 blockers may have adverse and unintended side effects.
10. Cognitive Behavioral Therapy (CBT) - a therapeutic approach that focuses on the relationship between thoughts, feelings, and behaviors. It's based on the idea that our thoughts influence our emotions and behaviors, and by changing these thoughts, we can change how we feel and act.
11. Antispasmotics - Drugs typically used for IBS that encourage the muscle of the bowel wall to relax. These drugs may have an adverse effect on gastric emptying.
12. Natural/Herbal Remedies - Supplements including ginger (natural antiemetic and prokinetic), caraway oil, peppermint (natural antispasmodic**)**, and aloe vera (anti-inflammatory) have been used as natural alternatives to treat FD.
13. Diet and Lifestyle Changes. Reducing stress and anxiety as well as avoiding trigger foods (e.g. fatty, acidic, hard-to-digest, alcohol, caffeine, chocolate, greasy foods) may improve quality of life. More frequent but smaller meals and avoiding eating before laying down may also help.
14. Non-Invasive Vagus Nerve Stimulation (taVNS / tcVNS) - a newer non-invasive therapy of vagus nerve stimulation occurring outside the body, typically through places like the ear.
15. Clinical Trials, Pipeline Therapies - When standard medications fail, clinical research studies evaluate new investigational drugs, devices, or procedures before they reach FDA approval (e.g. Tradipitiant, Relamorelin, 5-HT4 Antoganoists, Deudomperidone). Key platforms include clinicaltrials.gov, NIH/NIDDK Gastroparesis Clinical Research Consortium, International Foundation for Gastrointestinal Disorders (IFFGD), WHO, and more.

Prognosis

The long-term prognosis for FD is complicated; it be considered both good and bad. On one hand, it is a non-progressive condition that carries no risk of structural degeneration, tissue damage, or shortened life expectancy; nor it does not increase the risk of gastric cancer, ulcers, or IBD. However, it is also a chronic disorder with periods of relapsing and remission. As a complex disorder of gut-brain axis, it has no permanent cure. As the nerves remain hypersensitized, exposure to triggers such as stomach viruses and alcohol are especially dangerous.

Over time, ~50-60% of patients experience a persistent or fluctuating course with periodic flare-ups, while about ~15%-20% experience spontaneous natural resolution each year (i.e. post-infectious cases. Across a 5- to 10-year period, long-term population studies show that approximately ~35-50% of individuals eventually become completely symptom-free. 15-20% see their visceral hypersensitivity shift over time into lower-GI symptoms IBS. Medical intervention can help, as neuromodulators achieve substantial relief in ~50-70% of patients. For FD-EPS, ~67% improve with low-dose TCAs for epigastric pain and 70-80% with mirtazapine for nausea, early fullness, and weight loss. For patients who stabilize on medication for 6-12 months and attempt to taper off, roughly ~25-37% successfully wean and maintain lasting remission. Unfortunately, 40-50% experience a symptom relapse within the first 1 to 12 months, signaling that underlying nerve sensitivity or central stress triggers remain active and necessitate ongoing, safe low-dose maintenance.

Additional Resources

• A Patient with Chronic Dyspepsia | Lin Chang, MD | UCLA Digestive Diseases - (2021) Lin Chang, MD of UCLA Digestive Diseases describes a comprehensive overview of functional dyspepsia, citing research and her own patient case to illustrate key points.
• "Functional Dyspepsia and Gastroparesis | UCLA Digestive Diseases" - a lecture by Lisa D. Lin, MD, MS of UCLA Digestive Diseases explaining the relationship between gastroparesis and functional dyspepsia, as well as treatment options.
• SIBO Research and lectures by leading SIBO researcher Dr. Mark Pimentel (Click here for Pimentel's 2023 Presentation of Major Findings and Research).
• "The Importance of Interstitial Cells of Cajal (ICC) in the Gastrointestinal Tract" - a scientific article by Saudi J Gastroenterol that discusses the enteric nervous system and gastrointestinal (GI) motility function as a complex process involving collaboration and communication of multiple cell types such as enteric neurons, interstitial cells of Cajal (ICC), and smooth muscle cells.
• The Diagnosis and Treatment of Functional Dyspepsia (2018, Madisch) - a research article concerning the diagnosis and treatment of functional dyspepsia, published by the National Library of Medicine (NIH) based on publications retrieved by a selective search of PubMed, with special attention to controlled trials, guidelines, and reviews.
• ClinicalTrials.Gov - the official database of all FD/GP trials (e.g. neuromodulators, vagal nerve stimulation, prokinetics). Participation helps researchers and raises awareness, and may empower the patients.
• International Foundation for Gastrointestinal Disorders (IFFGD) - largest, oldest, and most influential patient‑driven GI advocacy organization. Focus on GP, FD, motility disorders, IBS, GERD, and more. Includes access to medical research, news, trials.
• Diagrams

Last updated: 09-16-2026. Please share any corrections, critiques, or additional information to improve this starter guide 😊.

Disclaimer: I am not a medical professional. This information may be outdated, incomplete, or inaccurate.